Integral BioSystems to present UV-protective OcuHeal-UV400+ eyedrop data at ARVO 2026

By AI, Created 9:42 AM UTC, May 20, 2026, /AGP/ – Integral BioSystems will present poster data on OcuHeal-UV400+, a UV-blocking antioxidant eyedrop, on May 5 at the 2026 ARVO Convention in Denver. The company says the lipid nanoparticle formulation is designed to protect corneal cells from UV damage and oxidative stress, with potential uses for digital eye strain and other ocular disorders.

Why it matters: - OcuHeal-UV400+ is aimed at eye damage linked to UV exposure, blue light and oxidative stress. - The formulation is designed to protect corneal epithelial cells and support healing in injured corneal tissue. - If commercialized, Integral BioSystems says the product could also address digital strain from prolonged computer use.

What happened: - Integral BioSystems will present data on OcuHeal-UV400+ at the Association for Research in Vision and Ophthalmology Convention in Denver. - The presentation is scheduled for May 5, 2026, from 1:15 p.m. to 3:00 p.m. - The poster is listed as Presentation Number 2967 - 0143 in Session 341, “Corneal disease and drug delivery.” - The presentation title is “OcuHeal-UV400+ Eyedrops Protect HCEC from UV-Induced Damage by Scavenging of Reactive Oxidative Species.” - The authors are Koushik Barman, Samuel Harris, Elliot Coleman, Laura Belen, Kevin Ward and Shikha Barman.

The details: - OcuHeal-UV400+ is part of Integral BioSystems’ pipeline of products in development based on a lipid nanoparticle platform. - The eyedrop uses a GRAS, plant-based compound inside nanostructured, liquid-crystalline lipid nanoparticles. - The compound has a high molar extinction coefficient and blocks both UV-A and UV-B. - The encapsulated LNP also blocks blue light. - The formulation is biocompatible with corneal epithelial cells. - The product quenches reactive free radicals generated by stressors such as particulate pollution. - The product elicits anti-fibrotic healing in injured corneal tissues. - Integral BioSystems says worldwide reports of ocular tissue disorders caused by UV radiation underscore the need for this type of product. - Integral BioSystems describes itself as a specialty drug delivery contract research firm focused on formulation and analytical development of small molecules and biologics. - The company says its hybrid business model has enabled proprietary innovations. - OcuHeal and NanoM-Wafer technologies have been fully patented in 14 global jurisdictions, including Europe, the U.S., Canada, India, China and Japan. - Additional PCT applications are pending as the technologies evolve.

Between the lines: - The ARVO poster gives Integral BioSystems a venue to show preclinical or early-stage data to ophthalmology researchers and potential partners. - The emphasis on UV-A, UV-B and blue-light blocking suggests the company is positioning the product for both disease prevention and broader eye-protection uses. - The patent footprint signals the company is trying to protect platform technologies across major markets while it develops the pipeline.

What’s next: - Integral BioSystems plans to disclose more details during the ARVO poster session on May 5, 2026. - The company is inviting partnership inquiries at info@integralbiosystems.com.